CANTEL MEDICAL CORP. (NYSE:CMD) Files An 8-K Changes in Registrant’s Certifying Accountant

Item 4.01. Changes in Registrants Certifying Accountant.

On May31, 2017, following careful deliberation and a competitive
process, the Audit Committee (the Committee) of the Board of
Directors of Cantel Medical Corp. (the Company) approved the
appointment of Deloitte Touche LLP (Deloitte) as the Companys
independent registered public accounting firm for the fiscal year
ending July31, 2018, and the dismissal of Ernst Young LLP (EY) as
the Companys independent registered public accounting firm,
effective upon completion of EYs audits of the Companys
consolidated financial statements for the fiscal year ending
July31, 2017 (and the effectiveness of internal control over
financial reporting as of July31, 2017), and the issuance of
their reports thereon to be included in the filing of the related
Form10-K. Deloitte was informed of the appointment and EY was
informed of the dismissal on May31, 2017.

During the fiscal years ended July31, 2016 and 2015 and in the
subsequent interim period through May31, 2017, there were (i)no
disagreements (as that term is described in Item 304(a)(1)(iv)of
Regulation S-K and the related instructions) between the Company
and EY on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure,
which disagreements, if not resolved to the satisfaction of EY,
would have caused EY to make reference to the subject matter of
such disagreements in its reports on the consolidated financial
statements for such years, and (ii)no reportable events (as that
term is described in Item 304(a)(1)(v)of Regulation S-K). EYs
reports on the consolidated financial statements of the Company
for the fiscal years ended July31, 2016 and 2015 did not contain
any adverse opinion or disclaimer of opinion, and were not
qualified or modified as to uncertainty, audit scope or
accounting principles. EYs audit reports on the effectiveness of
internal control over financial reporting as of July31, 2016 and
2015 did not contain an adverse opinion, nor were they qualified
or modified.

The Company provided EY with a copy of this Current Report on
Form8-K prior to its filing with the U.S. Securities and Exchange
Commission (SEC) and requested that EY furnish the Company with a
letter addressed to the SEC stating whether it agrees with the
above statements. A copy of EYs letter, dated June2, 2017, is
filed as Exhibit16.1 to this Current Report on Form8-K.

During the fiscal years ended July31, 2016 and 2015 and in the
subsequent interim period through May31, 2017, neither the
Company nor anyone acting on its behalf consulted Deloitte
regarding either (i)the application of accounting principles to a
specified transaction, either completed or proposed, or the type
of audit opinion that might be rendered with respect to the
consolidated financial statements of the Company, and neither a
written report nor oral advice was provided to the Company by
Deloitte that Deloitte concluded was an important factor
considered by the Company in reaching a decision as to any
accounting, auditing or financial reporting issue; or (ii)any
matter that was the subject of a disagreement (as that term is
used in Item 304(a)(1)(iv)of Regulation S-K and the related
instructions) or a reportable event (as that term is defined in
Item 304(a)(1)(v)of Regulation S-K).

Item 9.01. Financial Statements and Exhibits

(d)Exhibits.

About CANTEL MEDICAL CORP. (NYSE:CMD)

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.

CANTEL MEDICAL CORP. (NYSE:CMD) Recent Trading Information

CANTEL MEDICAL CORP. (NYSE:CMD) closed its last trading session up +1.55 at 81.00 with 183,512 shares trading hands.